Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay

In March, BioMark Diagnostics Inc BMKDF, a Canada-based liquid biopsy company, released data suggesting that Pulmonary Neuroendocrine Tumors (NETs) are reprogramming their metabolism as reflected by the presence of a panel of distinct metabolic biomarkers.
A logistic regression model with eight metabolites could discriminate neuroendocrine lung tumors from controls (AUC = 0.91 for NETs vs. controls).
The company says metabolomics is a more predictable diagnostic marker, and the metabolic difference between individuals is much smaller than that of genes and proteins.
BioMark focuses on hard-to-detect and diagnosing cancers to help select more effective treatments faster.
Novel liquid biopsy data in neuroendocrine tumors (NETs) was presented at USCAP.
The study included 120 plasma samples from patients with biopsy-confirmed NET and 227 control patients and is one of the largest ever reported.
It discovered a panel of metabolic biomarkers that can diagnose NETs and distinguish subtypes from each other and NSCLC.
The results suggest that this metabolic panel could allow the implementation of a routine screening test for NETs.
A larger sponsored prospective multimodal trial is being conducted involving seven hospitals and an n=3000.
The study will further confirm the clinical application of this validated panel of biomarkers for early lung cancer diagnosis.
AstraZeneca plc AZN and Pfizer Inc PFE, along with IUCPQ, are involved in the study. Results are expected later in Q3/Q4.
Image by PDPics from Pixabay

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga